A Study To Evaluate The Efficacy Of Enbrel (REGISTERED) Etanercept Over A Period Of 12 Months In The Routine Treatment Of Patients With Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis, Or Plaque Psoriasis. (ADEQUATE)

Pfizer

Status: Completed

Conditions: Plaque Psoriasis; Axial Spondyloarthritis; Psoriatic Arthritis; Rheumatoid Arthritis

Treatments: Drug: Etanercept

Study type: Observational

Funder types: Industry

Identifiers

NCT02486302

B1801385

ADEQUATE (Other Identifier)

Details and patient eligibility

About

The purpose of this non-interventional study is to evaluate the efficacy of etanercept during routine clinical use over a maximum of 12 months in patients with rheumatoid arthritis (RA), psoriatic arthritis(PsA), axial spondyloarthritis(axSpA) or plaque psoriasis (PsO). In so doing, particular attention will be paid to the proportion of those patients who only attain the desired treatment goal after 12 weeks of treatment. The primary efficacy end point for the study is the proportion of patients who attain the desired treatment goal after 12 and 24 weeks,

Enrollment: 1,534 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Confirmed diagnosis of RA, axSpA, PsA or PsO
• No prior treatment with etanercept and eligibility for treatment with etanercept according to the summary of product characteristics.

Exclusion criteria

• The contraindications, special warnings, and precautions according to the summary of product characteristics for etanercept shall apply.
• The additional documentation of the patient in another post-marketing study with etanercept is not permitted.

Trial design

1,534 participants in 1 patient group

Observation Group

Treatment:

Drug: Etanercept